메뉴 건너뛰기
.. 내서재 .. 알림
소속 기관/학교 인증
인증하면 논문, 학술자료 등을  무료로 열람할 수 있어요.
한국대학교, 누리자동차, 시립도서관 등 나의 기관을 확인해보세요
(국내 대학 90% 이상 구독 중)
로그인 회원가입 고객센터 ENG
주제분류

추천
검색

논문 기본 정보

자료유형
학술저널
저자정보
Jiesuck Park (Seoul National University Hospital) Jung-Kyu Han (Seoul National University Hospital) Jeehoon Kang (Seoul National University Hospital) In-Ho Chae (Seoul National University Bundang Hospital) Sung Yun Lee (Inje University Ilsan Paik Hospital) Young Jin Choi (Sejong General Hospital) Jay Young Rhew (Presbyterian Medical Center) Seung-Woon Rha (Korea University Guro Hospital) Eun-Seok Shin (Ulsan University Hospital) Seong-Ill Woo (Inha University Hospital) Han Cheol Lee (Pusan National University Hospital) Kook-Jin Chun (Pusan National University Yangsan Hospital) DooIl Kim (Inje University College of Medicine) Jin-Ok Jeong (Chungnam National University College of Medicine) Jang-Whan Bae (Chungbuk National University College of Medicine) Han-Mo Yang (Seoul National University Hospital) Kyung Woo Park (Seoul National University Hospital) Hyun-Jae Kang (Seoul National University Hospital) Bon-Kwon Koo (Seoul National University Hospital) Hyo-Soo Kim (Seoul National University Hospital)
저널정보
대한심장학회 Korean Circulation Journal Korean Circulation Journal Vol.52 No.7
발행연도
2022.7
수록면
544 - 555 (12page)
DOI
https://doi.org/10.4070/kcj.2021.0395

이용수

표지
📌
연구주제
📖
연구배경
🔬
연구방법
🏆
연구결과
AI에게 요청하기
추천
검색

초록· 키워드

오류제보하기
Background and Objectives: The outcome benefits of β-blockers in chronic coronary artery disease (CAD) have not been fully assessed. We evaluated the prognostic impact of β-blockers on patients with chronic CAD after percutaneous coronary intervention (PCI). Methods: A total of 3,075 patients with chronic CAD were included from the Grand Drug-Eluting Stent registry. We analyzed β-blocker prescriptions, including doses and types, in each patient at 3-month intervals from discharge. After propensity score matching, 1,170 pairs of patients (β-blockers vs. no β-blockers) were derived. Primary outcome was defined as a composite endpoint of all-cause death and myocardial infarction (MI). We further analyzed the outcome benefits of different doses (low-, medium-, and high-dose) and types (conventional or vasodilating) of β-blockers. Results: During a median (interquartile range) follow-up of 3.1 (3.0?3.1) years, 134 (5.7%) patients experienced primary outcome. Overall, β-blockers demonstrated no significant benefit in primary outcome (hazard ratio [HR], 0.88; 95% confidence interval [CI], 0.63?1.24), all-cause death (HR, 0.87; 95% CI, 0.60?1.25), and MI (HR, 1.25; 95% CI, 0.49?3.15). In subgroup analysis, β-blockers were associated with a lower risk of all-cause death in patients with previous MI and/or revascularization (HR, 0.38; 95% CI, 0.14?0.99) (p for interaction=0.045). No significant associations were found for the clinical outcomes with different doses and types of β-blockers. Conclusions: Overall, β-blocker therapy was not associated with better clinical outcomes in patients with chronic CAD undergoing PCI. Limited mortality benefit of β-blockers may exist for patients with previous MI and/or revascularization.

목차

등록된 정보가 없습니다.

참고문헌 (0)

참고문헌 신청

함께 읽어보면 좋을 논문

논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!

이 논문의 저자 정보

최근 본 자료

전체보기

댓글(0)

0